Senzime Management

Management criteria checks 3/4

Senzime's CEO is Philip Siberg, appointed in May 2023, has a tenure of 1.5 years. total yearly compensation is SEK4.61M, comprised of 55.2% salary and 44.8% bonuses, including company stock and options. directly owns 0.62% of the company’s shares, worth €350.32K. The average tenure of the management team and the board of directors is 2.8 years and 3.7 years respectively.

Key information

Philip Siberg

Chief executive officer

SEK 4.6m

Total compensation

CEO salary percentage	55.2%
CEO tenure	1.5yrs
CEO ownership	0.6%
Management average tenure	2.8yrs
Board average tenure	3.7yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Philip Siberg's remuneration changed compared to Senzime's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2024	n/a	n/a	-SEK 131m
Jun 30 2024	n/a	n/a	-SEK 130m
Mar 31 2024	n/a	n/a	-SEK 131m
Dec 31 2023	SEK 5m	SEK 3m	-SEK 134m
Sep 30 2023	n/a	n/a	-SEK 138m
Jun 30 2023	n/a	n/a	-SEK 137m
Mar 31 2023	n/a	n/a	-SEK 143m
Dec 31 2022	SEK 450k	n/a	-SEK 133m
Sep 30 2022	n/a	n/a	-SEK 114m
Jun 30 2022	n/a	n/a	-SEK 104m
Mar 31 2022	n/a	n/a	-SEK 86m
Dec 31 2021	SEK 400k	n/a	-SEK 82m
Sep 30 2021	n/a	n/a	-SEK 74m
Jun 30 2021	n/a	n/a	-SEK 66m
Mar 31 2021	n/a	n/a	-SEK 56m
Dec 31 2020	SEK 100k	n/a	-SEK 47m
Sep 30 2020	n/a	n/a	-SEK 41m
Jun 30 2020	n/a	n/a	-SEK 36m
Mar 31 2020	n/a	n/a	-SEK 32m
Dec 31 2019	SEK 100k	n/a	-SEK 33m
Sep 30 2019	n/a	n/a	-SEK 34m
Jun 30 2019	n/a	n/a	-SEK 33m
Mar 31 2019	n/a	n/a	-SEK 30m
Dec 31 2018	SEK 100k	n/a	-SEK 24m
Sep 30 2018	n/a	n/a	-SEK 19m
Jun 30 2018	n/a	n/a	-SEK 16m
Mar 31 2018	n/a	n/a	-SEK 13m
Dec 31 2017	SEK 131k	n/a	-SEK 13m

Compensation vs Market: Philip's total compensation ($USD417.82K) is about average for companies of similar size in the German market ($USD471.14K).

Compensation vs Earnings: Philip's compensation has increased whilst the company is unprofitable.

CEO

Philip Siberg (51 yo)

1.5yrs

Tenure

SEK 4,614,088

Compensation

Mr. Philip Siberg serves as the Chief Executive Officer of Stille Surgical, Inc. He serves as Chairman of the Board at Acarix AB (publ) since May 11, 2021. He was Co-Founder of Coala-Life Group AB (publ) a...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Philip Siberg	Chief Executive Officer	1.5yrs	SEK 4.61m	0.62% € 350.3k
Slavoljub Grujicic	Chief Financial Officer	2.8yrs	no data	0.022% € 12.4k
Johanna Tulkki	Chief Operating Officer	4.8yrs	no data	no data
Fredrik Norrby	Chief Technology Officer	1.8yrs	no data	no data
Rianne Waninge	Application Scientist	no data	no data	no data
Paula Treutiger	Head of Communication & Investor Relations	2.8yrs	no data	no data
Anders Selin	Executive Vice President of Sales	5.2yrs	no data	no data
Michael Noble	Vice President Global Marketing	less than a year	no data	no data
Anders Jacobson	Chief Innovation Officer	8.8yrs	no data	0.014% € 7.9k
Catrin Molund	Executive Vice President of Business Development	3.8yrs	SEK 163.00k	no data
Johanna Faris	Head of Q/RA/S	less than a year	no data	0.0014% € 776.6

2.8yrs

Average Tenure

54yo

Average Age

Experienced Management: 6YC's management team is considered experienced (2.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Per Wold-Olsen	Chairman of the Board	less than a year	no data	0.56% € 316.0k
Goran Brorsson	Independent Director	1.5yrs	SEK 131.00k	0.090% € 50.4k
Adam Dahlberg	Vice Chairman of the Board	24.8yrs	SEK 350.00k	5.55% € 3.1m
Eva Walde	Independent Director	3.7yrs	SEK 210.00k	no data
Sorin Brull	Chief Medical Officer	8.8yrs	SEK 1.31m	3.33% € 1.9m
Alfredo Abad-Gurumeta	Member of Scientific Advisory Board	no data	no data	no data
Bela Fulesdi	Member of Scientific Advisory Board	no data	no data	no data
Guy Cammu	Member of Scientific Advisory Board	no data	no data	no data
Hans Boer	Member of Scientific Advisory Board	no data	no data	no data
Claude Meistelman	Member of Scientific Advisory Board	no data	no data	no data
Jennifer Hunter	Member of Scientific Advisory Board	no data	no data	no data
Casper Claudius	Member of Scientific Advisory Board	no data	no data	no data

3.7yrs

Average Tenure

68yo

Average Age

Experienced Board: 6YC's board of directors are considered experienced (3.7 years average tenure).

Senzime Management

Management criteria checks 3/4

Key information

Recent management updates

Chairman of the Board recently bought €106k worth of stock

Less than half of directors are independent

Senzime AB (publ) Announces Board Changes

Less than half of directors are independent

Senzime AB (Publ) Appoints Philip Siberg as Chief Executive Officer

Less than half of directors are independent

Recent updates

Chairman of the Board recently bought €106k worth of stock

New minor risk - Profitability

Third quarter 2024 earnings released: kr0.26 loss per share (vs kr0.33 loss in 3Q 2023)

Senzime AB (publ) to Report Q1, 2025 Results on May 07, 2025

Senzime Successfully Unveils Next-Generation TetraGraph Quantitative Train-Of-Four Monitor at ANESTHESI Technology 2024

Senzime to Launch Next-Generation Tetragraph System At Anesthesiology 2024 Conference

Second quarter 2024 earnings released

Senzime AB (publ.) Announces European Patent Office Issues New Patent Protecting Unique Capabilities of the Senzime TetraGraph System

New minor risk - Profitability

Full year 2023 earnings released: kr1.45 loss per share (vs kr1.99 loss in FY 2022)

Senzime AB (publ) to Report Q3, 2024 Results on Nov 06, 2024

Full year 2023 earnings released: kr1.45 loss per share (vs kr1.99 loss in FY 2022)

Less than half of directors are independent

Senzime AB (publ) Announces Board Changes

Senzime Announces New Clinical Study with the Tetragraph System Published in the British Journal of Anesthesia Open

Third quarter 2023 earnings released: kr0.33 loss per share (vs kr0.74 loss in 3Q 2022)

Senzime AB (publ) to Report Fiscal Year 2023 Results on Feb 15, 2024

New major risk - Shareholder dilution

Senzime Launches Tetras Sensitive, the Market's First Sensor for Nemomuscular Monitoring of Patients with Sensitive Skin

No longer forecast to breakeven

Senzime AB (publ) Announces New Study Valued the Feasibility of TetraSens Pediatric Disposable Sensor

Senzime AB (publ) Presents Scientific Study at Euroanaesthesia 2023 and Validates New TetraGraph Electromyographic Detection Algorithm

Less than half of directors are independent

No longer forecast to breakeven

Senzime AB (Publ) Appoints Philip Siberg as Chief Executive Officer

First quarter 2023 earnings released: kr0.42 loss per share (vs kr0.33 loss in 1Q 2022)

Less than half of directors are independent

Independent Chairman recently bought €66k worth of stock

Less than half of directors are independent

Senzime Receives Approval for Its Pediatric Sensor in Japan

Full year 2022 earnings released: kr1.99 loss per share (vs kr1.31 loss in FY 2021)

Senzime AB (publ) to Report Q3, 2023 Results on Oct 26, 2023

Senzime AB (publ) to Report Fiscal Year 2022 Results on Feb 01, 2023

Senzime Receives First Contract for TetraSens Pediatric in the US

Less than half of directors are independent

Senzime's TetraGraph supported by new European clinical guidelines for patient monitoring

Senzime AB (publ) Provides Earnings Guidance for 2025

Senzime AB (Publ) Announces Board Appointments

Senzime AB (publ) Receives FDA 510K-Clearance for New Disposable Sensor Intended for Monitoring of Children

Senzime AB (publ) Announces Launch of TetraGraph Xcom Interface to Electronic Medical Records

Forecast breakeven date pushed back to 2024

Second quarter 2022 earnings released: kr0.63 loss per share (vs kr0.35 loss in 2Q 2021)

Less than half of directors are independent

Senzime AB (publ) (OM:SEZI) entered into an agreement to acquire Respiratory Motion, Inc. for $44 million.

First quarter 2022 earnings released: kr0.33 loss per share (vs kr0.27 loss in 1Q 2021)

Less than half of directors are independent

Senzime AB (Publ) Applies for FDA Approval for A New Single-Use Sensor for Children

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Senzime Announces Anesthesia Patient Safety Foundation Recommends Use of A Quantitative Monitor Whenever A Neuromuscular Blocking Agent Is Administered

Senzime AB (Publ) Announces Japanese Study Confirms Tetragraph Monitor as a Better Indicator of Appropriate Reversal Dose of Sugammadex and Adequate Recovery of Neuromuscular Function Than Amg-Based Tof- Watch SX

Third quarter 2021 earnings released: kr0.31 loss per share (vs kr0.20 loss in 3Q 2020)

Second quarter 2021 earnings released: kr0.35 loss per share (vs kr0.23 loss in 2Q 2020)

First quarter 2021 earnings released: kr0.27 loss per share (vs kr0.17 loss in 1Q 2020)

Senzime AB (publ) Appoints Eva Walde as New Member of the Board of Directors

Full year 2020 earnings released: kr0.84 loss per share (vs kr0.68 loss in FY 2019)

Senzime AB (publ) to Report Q3, 2021 Results on Nov 12, 2021

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age